2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
808
Precursor Cell Lymphoblastic Leukemia-Lymphoma
171
Recurrence
141
Neoplasms, Plasma Cell
111
Lymphoma
93
Leukemia
91
Neoplasms
81
Burkitt Lymphoma
57
Vomiting
51
Lymphoma, Non-Hodgkin
50
Immunoglobulin Light-chain Amyloidosis
50
Lymphoma, Large B-Cell, Diffuse
44
Nausea
38
Lymphoma, Mantle-Cell
38
Prostatic Neoplasms
31
Lymphoma, Follicular
30
Hodgkin Disease
29
Waldenstrom Macroglobulinemia
27
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
27
Neoplasm Metastasis
26
Leukemia, Lymphocytic, Chronic, B-Cell
26
Carcinoma, Non-Small-Cell Lung
26
Leukemia, Myeloid, Acute
25
Breast Neoplasms
25
Lung Neoplasms
23
Amyloidosis
21
Leukemia, Biphenotypic, Acute
18
Lymphoma, B-Cell, Marginal Zone
17
Lymphoma, Extranodal NK-T-Cell
16
Smoldering Multiple Myeloma
15
Interventions
enzalutamide
7
Abiraterone Acetate
4
abiraterone
3
Prednisone
3
Docetaxel
3
sapanisertib
1
relugolix
1
pembrolizumab
1
onvansertib
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
apalutamide
1
abemaciclib
1
Prednisolone
1
PF06821497
1
Methylprednisolone
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-Resistant Prostate Cancer
×
Dexamethasone
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled